Selected Grants
Single arm Study of ALXN1210 in Complement Inhibitor Treatment-Naive Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2017 - 2022A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2017 - 2020Vifor PA21 Phaslyra
Clinical TrialPrincipal Investigator · Awarded by Vifor Fresenius Medical Care Renal Pharma · 2016 - 2019An observational, non-interventional, multi-center, multi-national study of patients with Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2013 - 2018External Relationships
- National kidney foundation, North Carolina Chapter
- Nova Nordisk Foundation
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.